MiRNAs: main players of cancer drug resistance target ABC transporters.
Saved in:
| Title: | MiRNAs: main players of cancer drug resistance target ABC transporters. |
|---|---|
| Authors: | Mohammadi F; Department of Veterinary, Agriculture Faculty, Kermanshah Branch, Islamic Azad University, Kermanshah, Iran., Nejatollahi M; Research Center for High School Students, Education System Zanjan Province, Zanjan, Iran., Sheikhnia F; Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran.; Department of Clinical Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran., Ebrahimi Y; Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran.; Department of Clinical Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran., Mohammadi M; Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Rashidi V; Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran., Alizadeh-Fanalou S; Department of Clinical Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran., Azizzadeh B; Department of Biochemistry, School of Medicine, Ilam University of Medical Sciences, Ilam, Iran., Majidinia M; Solid Tumor Research Center, Cellular and Molecular Medicine Research Institute, Urmia University of Medical Sciences, Urmia, Iran. majidinia.m@umsu.ac.ir. |
| Source: | Naunyn-Schmiedeberg's archives of pharmacology [Naunyn Schmiedebergs Arch Pharmacol] 2025 Jun; Vol. 398 (6), pp. 6239-6291. Date of Electronic Publication: 2025 Jan 14. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0326264 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1912 (Electronic) Linking ISSN: 00281298 NLM ISO Abbreviation: Naunyn Schmiedebergs Arch Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
